# A Phase 1b Study of GKL-006 Injection in Patients With Unresectable Hepatocellular Carcinoma

Source: https://onco.cc/trials/nct07713290/  
OnCo record `nct07713290` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of GKL-006 Injection run by Beijing Gene Key Life Technology Co., Ltd, active and no longer recruiting.

## Summary

A Phase 1b Study of GKL-006 Injection in Patients With Unresectable Hepatocellular Carcinoma is a phase 1 interventional study registered as NCT07713290 by Beijing Gene Key Life Technology Co., Ltd, with 6 participants planned, started 2025-04-03. Conditions recorded: Hepatocellular Carcinoma (HCC) and Unresectable Hepatocellular Cancer. Interventions recorded: GKL-006 Injection and Transarterial chemoembolization (TACE).

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07713290
- Phase: 1
- Setting: An Open-Label, Multiple-Dose Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GKL-006 Injection in Patients With Unresectable Hepatocellular Carcinoma
- Sponsor: Beijing Gene Key Life Technology Co., Ltd
- Enrolled: 6

## Sources

- ClinicalTrials.gov NCT07713290: https://clinicaltrials.gov/study/NCT07713290

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)
- drugs: [GKL-006 Injection](https://onco.cc/drugs/gkl-006/)
- companies: [Beijing Gene Key Life Technology](https://onco.cc/companies/beijing-gene-key-life-technology/)

---
JSON: https://onco.cc/api/v1/entities/nct07713290.json